Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Sanctura XR NDA accepted for review

Dec. 15, 2006

Schwarz Pharma transfers urology R&D project to 4SC

Dec. 15, 2006

New agents for urinary incontinence emerge from Astellas Pharma R&D

Dec. 13, 2006

MM-101 ameliorates vesical dysfunction in diabetes model

Dec. 11, 2006

SMP-986 improves voiding efficiency in anesthetized dogs

Dec. 7, 2006

BXL-628 has relevant molecular effects in experimental autoimmune prostatitis

Dec. 7, 2006

Pfizer's novel EP1 receptor antagonist may be useful to treat incontinence

Dec. 4, 2006

Novel agents for treating renal and urological disorders disclosed in recent patents

Dec. 1, 2006

Cetrorelix set to begin phase III for BPH

Dec. 1, 2006

Targets in nephrology

Nov. 29, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...